- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
April 23, 2024David Martinez Recognized Among Top 100 Lawyers in Los Angeles by LA Business Journal
-
April 15, 2024Robins Kaplan Named to 2024 BTI Client Service A-Team
-
April 9, 2024Robins Kaplan LLP Files Complaint Against Social Media Giants Meta, Snap, TikTok on Behalf of Spirit Lake Nation, Menominee Indian Tribe of Wisconsin
-
April 30, 2024Navigating Generational Dynamics
-
May 2-3, 2024ACI Advanced Forum on Managed Care Disputes and Litigation
-
May 6, 2024Litigating with the Legends
-
March 2024e-Commerce: Pitfalls and Protections
-
March 22, 2024‘In re Cellect’:
-
March 14, 2024How Many Cases Have You Tried to a Verdict?
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Bayer Pharma AG v. Watson Labs., Inc
A proposed combination will not render a patent obvious wherein the proposed combination improperly relies on hindsight.
April
Case Name: Bayer Pharma AG v. Watson Labs., Inc., Civ. No. 12-cv-517 (GMS), 2016 U.S. Dist. LEXIS 55752 (D. Del. Apr. 27, 2016) (Sleet, J.)
Drug Product and Patent(s)-in-Suit: Staxyn® (vardenafil hydrochloride trihydrate); U.S. Patent No. 8,613,950 (“the ’950 patent”)
Nature of the Case and Issue(s) Presented: Watson asserted that that claims of the ’950 patent were invalid as obvious for two reasons: (i) combining vardenafil hydrochloride trihydrate with the sugar alcohol excipients mannitol and sorbitol into a known orally disintegrating tablet (“ODT”) dosage form was taught by the prior art and would have been obvious to the person of ordinary skill, particularly in view of the taste profiles and favorable disintegration properties of the sugars; and (ii) competitive pressure would have motivated one skilled in the art to derive the claimed subject.
Bayer responded that one of skill would not have been motivated to modify the dosage type of vardenafil to ODT as there were no known problems with the digestible version of vardenafil in Levitra®. In addition, there were very few ODT formulations on the market or being contemplated at the time of the invention. Lastly, one of skill would not be motivated to use an ODT dosage with vardenafil because of the taste profile.
The court agreed with Bayer and found that Watson had not met is clear and convincing burden of proving invalidity by obviousness.
Why Bayer Prevailed: The court agreed with Bayer that one of skill would not have modified the digestible version of vardenafil into an ODT dosage form because there had not been any known problems with the digestible version. Further, literature at the time demonstrated that ODT dosage forms were not that common, and, in particular, no compound or contemplated compound to treat erectile dysfunction was offered in an ODT dosage form. The court also rejected Watson’s argument that one of skill would have used her own personal taste to determine if an ODT dosage form of vardenafil would be sufficient. Lastly, the court found that the evidence in the prior art contemplated the use of only one sugar in such formulations, and not two as suggested by Watson.
The court also found that secondary considerations of non-obviousness favored Bayer. In particular, there were unexpected results related to the bioavailability of the ODT dosage form as compared to the digestible form. Likewise, there was evidence that Watson did copy the claimed invention, and not just simply by filing an ANDA.
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.